Adult ALL Treatment at Diagnosis

Leukemia, Lymphocytic, Acute Clinical Trial

— LAL2000  

Official title:

GIMEMA Guidelines for the Treatment of Adult ALL Affected Patients at Diagnosis

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00537550
• Other study ID #: LAL2000
• Status: Completed
• Phase: N/A
• First received: September 27, 2007
• Last updated: September 28, 2007
• Start date: July 2000
• Est. completion date: June 2006

Study information

• Verified date: September 2007
• Source: Gruppo Italiano Malattie EMatologiche dell'Adulto
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The present study has been designed to give participating centers the possibility of better understanding the diagnostic and prognostic factors of ALL patients.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 0
• Est. completion date: June 2006
• Accepts healthy volunteers: No
• Gender: All
• Age group: 14 Years to 60 Years

Eligibility

Inclusion Criteria:

• Diagnosis of acute lymphoblastic leukemia (ALL)

• Negative myeloperoxidase stain

• Phenotype T (ALL-T) and B(ALL-B)

Exclusion Criteria:

• Creatinine > 2.5mg/dL after adequate hydratation

• LVEF <50%

• Presence of documented infections not responding to antibiotic and/or antifungal therapy

• Presence of concomitant malignant diseases

• Absence of any psychological condition that does not allow to intake high doses of cortisone

• Patients who have received any antineoplastic chemiotherapy for more than 5 days

• Patients who have received any steroids for more than 10 days

Related Conditions & MeSH terms

• Leukemia, Lymphocytic, Acute
• Leukemia, Lymphoid
• Precursor Cell Lymphoblastic Leukemia-Lymphoma

Intervention

Drug:
• Vincristine
Steroids pre-treatment
• Vincristin, Daunorubicine, Asparaginase, Methotrexate
Induction therapy

Locations

Country	Name	City	State
Italy	Az. Ospedaliera S. G. Moscati	Avellino
Italy	Ist.Ematologia e Oncologia Medica L.e A. Seragnoli	Bologna
Italy	Ospedale Reg. A di Summa	Brindisi
Italy	Istituto di Ematologia- Ospedale San Carlo	Potenza
Italy	Policlinico G.B. Rossi	Verona

Sponsors (1)

Lead Sponsor	Collaborator
Gruppo Italiano Malattie EMatologiche dell'Adulto

Country where clinical trial is conducted

Italy,